Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

NCT04554680 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: dabrafenib and trametinib

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]